Previous 10 | Next 10 |
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will participate in the upcoming Piper Sandler 32 nd Annual Virtual Healthcare Conference. ...
AtriCure, Inc. (ATRC) Q3 2020 Results Conference Call November 05, 2020 04:30 PM ET Company Participants Lynn Lewis - Gilmartin Group Mike Carrel - President and CEO Angie Wirick - CFO Conference Call Participants Robby Marcus - JP Morgan Rick Wise - Stifel Danielle Antalffy - SVB Leerink Mat...
Image source: The Motley Fool. AtriCure Inc (NASDAQ: ATRC) Q3 2020 Earnings Call Nov 5, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: AtriCure Inc (ATRC) Q3 2020 Earnings Call Transcript
AtriCure (ATRC): Q3 GAAP EPS of -$0.11 beats by $0.23.Revenue of $54.76M (-3.3% Y/Y) beats by $5.39M.Shares +1.7% AH.Press Release For further details see: AtriCure EPS beats by $0.23, beats on revenue
Worldwide revenue of $54.8 million – a decrease of 3.3% year over year U.S. revenue of $44.7 million – a decrease of 3.1% year over year International revenue of $10.1 million – a decrease of 4.1% year over year AtriCure, Inc. ( Nasdaq: ATR...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2020 financial results on Thursday, November 5, 2020. AtriCure will host a con...
Thinly traded AtriCure ([[ATRC]] -9.4%) is under modest pressure out of the gate this morning on the heels of a bearish report from Kerrisdale Capital Management who believes its growth drivers face headwinds. Key points:The company's Convergent procedure is unlikely to gain traction consider...
Among other criticisms, Kerrisdale Capital cites valuation as part of its short thesis on Atricure (ATRC), given it's near the "highest valuation in its history."Investors' assumptions on a "widespread adoption" of the Convergent procedure and growth in surgical devices are "misplaced."Shares...
AtriCure's Convergent procedure, on which its hopes for growth are pinned, is unlikely to gain traction given a poor safety profile and lack of incremental efficacy relative to catheter-based procedures. The TAM for AtriCure's core surgical ablation products is much smaller than AtriC...
AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Morgan Stanley 18 th Annual Global Healthcare Conference being held virtually...
News, Short Squeeze, Breakout and More Instantly...
2024-07-31 08:00:12 ET Rick Wise from Stifel Nicolaus issued a price target of $26.00 for ATRC on 2024-07-31 06:57:00. The adjusted price target was set to $26.00. At the time of the announcement, ATRC was trading at $22. The overall price target consensus is at $56.00 w...
Worldwide revenue of $116.3 million – an increase of 15.2% year over year Positive cash flow generation of $8.1 million in second quarter 2024 AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), l...
CFSB Bancorp Inc. (CFSB) is expected to report for Q4 2024 Big 5 Sporting Goods Corporation (BGFV) is expected to report $-0.48 for Q2 2024 Canadian Pacific Kansas City Limited (CP) is expected to report $0.74 for Q2 2024 Captivision Inc. (CAPT) is expected to report for quarter end 2...